What is the first-line treatment for primary biliary cirrhosis (PBC)?

Ursodeoxycholic acid is recognized as the first-line treatment for primary biliary cirrhosis (PBC). This medication helps improve liver function by reducing the toxicity of bile acids, promoting the expulsion of bile from the liver, and slowing the progression of the disease. It has been shown to improve liver biochemistry and delay complications associated with PBC, making it an essential component of management for patients diagnosed with this condition.

The other treatment options, while used in various contexts, are not the primary choice for PBC. Corticosteroids may be employed in specific situations, particularly for patients with autoimmune features or severe symptoms, but they are not the first-line treatment for PBC itself. Liver transplantation is reserved for patients who develop end-stage liver disease or complications that can no longer be managed with pharmacologic therapies; it is a definitive treatment, but only indicated in advanced cases. Interferon therapy has been utilized for certain liver diseases but is not a standard treatment choice for PBC and is less effective than ursodeoxycholic acid. Therefore, attention to the specifics of PBC treatment consistently highlights ursodeoxycholic acid as the most effective and appropriate initial intervention.